What is the current valuation of the Human Biobanking Ownership Market?

The market valuation was 31.94 USD Billion in 2024. Read More

What is the projected market size for the Human Biobanking Ownership Market by 2035?

The projected valuation for 2035 is 54.75 USD Billion. Read More

What is the expected CAGR for the Human Biobanking Ownership Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.02%. Read More

Which segments are driving growth in the Human Biobanking Ownership Market?

Key segments include Research, Clinical Trials, Personalized Medicine, and Disease Prevention. Read More

What are the projected valuations for the Research segment by 2035?

The Research segment is projected to grow from 10.0 USD Billion to 17.0 USD Billion by 2035. Read More

How do public and private biobanks compare in terms of market valuation?

Public Biobanks are projected to range from 10.0 USD Billion to 17.0 USD Billion, while Private Biobanks are expected to grow from 12.0 USD Billion to 20.0 USD Billion. Read More

What types of samples are most commonly used in biobanking?

Blood Samples, Tissue Samples, Cell Lines, and Biological Fluids are the primary sample types utilized. Read More

What is the expected market performance for pharmaceutical companies in the biobanking sector?

Pharmaceutical Companies are projected to see a market range from 12.0 USD Billion to 20.0 USD Billion by 2035. Read More

Who are the key players in the Human Biobanking Ownership Market?

Key players include Biorepository, Global Biobank, Tissue Solutions, and Cleveland Clinic Biobank. Read More

What is the significance of personalized medicine in the Human Biobanking Ownership Market?

The Personalized Medicine segment is projected to grow from 7.0 USD Billion to 11.0 USD Billion by 2035, indicating its increasing relevance. Read More

Human Biobanking Ownership Market

ID: MRFR/HC/35956-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Human Biobanking Ownership Market Research Report: Size, Share, Trend Analysis By Applications (Research, Clinical Trials, Personalized Medicine, Disease Prevention), By Types of Biobank (Public Biobanks, Private Biobanks, Commercial Biobanks), By Sample Type (Blood Samples, Tissue Samples, Cell Lines, Biological Fluids), By End Use (Pharmaceutical Companies, Academic Institutions, Healthcare Providers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Human Biobanking Ownership Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.02%

2024 Market Size$ 31.94 Billion

2025 Market Size$ 33.54 Billion

2035 Market Size$ 54.75 Billion

Key Players

Biorepository

Global Biobank

Tissue Solutions

Cleveland Clinic Biobank

NHS Blood and Transplant

Krebsforschung

Trends

Emergence of Decentralized Biobanking Models
Increased Focus on Ethical Ownership
Technological Integration in Sample Management

Opportunities

Regulatory Support and Frameworks
Rising Demand for Personalized Medicine
Advancements in Research and Development

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Research
  2. 4.1.2 Clinical Trials
  3. 4.1.3 Personalized Medicine
  4. 4.1.4 Disease Prevention
2. 4.2 Healthcare, BY Type of Biobank (USD Billion)
  1. 4.2.1 Public Biobanks
  2. 4.2.2 Private Biobanks
  3. 4.2.3 Commercial Biobanks
3. 4.3 Healthcare, BY Sample Type (USD Billion)
  1. 4.3.1 Blood Samples
  2. 4.3.2 Tissue Samples
  3. 4.3.3 Cell Lines
  4. 4.3.4 Biological Fluids
4. 4.4 Healthcare, BY End Use (USD Billion)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Academic Institutions
  3. 4.4.3 Healthcare Providers
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Biorepository (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Global Biobank (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Tissue Solutions (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Cleveland Clinic Biobank (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 NHS Blood and Transplant (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Krebsforschung (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 BioBanking (FI)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Australian Biobank (AU)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY TYPE OF BIOBANK
5. 6.5 US MARKET ANALYSIS BY SAMPLE TYPE
6. 6.6 US MARKET ANALYSIS BY END USE
7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY TYPE OF BIOBANK
9. 6.9 CANADA MARKET ANALYSIS BY SAMPLE TYPE
10. 6.10 CANADA MARKET ANALYSIS BY END USE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
13. 6.13 GERMANY MARKET ANALYSIS BY TYPE OF BIOBANK
14. 6.14 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY END USE
16. 6.16 UK MARKET ANALYSIS BY APPLICATION
17. 6.17 UK MARKET ANALYSIS BY TYPE OF BIOBANK
18. 6.18 UK MARKET ANALYSIS BY SAMPLE TYPE
19. 6.19 UK MARKET ANALYSIS BY END USE
20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
21. 6.21 FRANCE MARKET ANALYSIS BY TYPE OF BIOBANK
22. 6.22 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
23. 6.23 FRANCE MARKET ANALYSIS BY END USE
24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY TYPE OF BIOBANK
26. 6.26 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
27. 6.27 RUSSIA MARKET ANALYSIS BY END USE
28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
29. 6.29 ITALY MARKET ANALYSIS BY TYPE OF BIOBANK
30. 6.30 ITALY MARKET ANALYSIS BY SAMPLE TYPE
31. 6.31 ITALY MARKET ANALYSIS BY END USE
32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
33. 6.33 SPAIN MARKET ANALYSIS BY TYPE OF BIOBANK
34. 6.34 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
35. 6.35 SPAIN MARKET ANALYSIS BY END USE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE OF BIOBANK
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
42. 6.42 CHINA MARKET ANALYSIS BY TYPE OF BIOBANK
43. 6.43 CHINA MARKET ANALYSIS BY SAMPLE TYPE
44. 6.44 CHINA MARKET ANALYSIS BY END USE
45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
46. 6.46 INDIA MARKET ANALYSIS BY TYPE OF BIOBANK
47. 6.47 INDIA MARKET ANALYSIS BY SAMPLE TYPE
48. 6.48 INDIA MARKET ANALYSIS BY END USE
49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
50. 6.50 JAPAN MARKET ANALYSIS BY TYPE OF BIOBANK
51. 6.51 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
52. 6.52 JAPAN MARKET ANALYSIS BY END USE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE OF BIOBANK
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE OF BIOBANK
59. 6.59 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USE
61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
62. 6.62 THAILAND MARKET ANALYSIS BY TYPE OF BIOBANK
63. 6.63 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
64. 6.64 THAILAND MARKET ANALYSIS BY END USE
65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY TYPE OF BIOBANK
67. 6.67 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
68. 6.68 INDONESIA MARKET ANALYSIS BY END USE
69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE OF BIOBANK
71. 6.71 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY TYPE OF BIOBANK
76. 6.76 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
77. 6.77 BRAZIL MARKET ANALYSIS BY END USE
78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
79. 6.79 MEXICO MARKET ANALYSIS BY TYPE OF BIOBANK
80. 6.80 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
81. 6.81 MEXICO MARKET ANALYSIS BY END USE
82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE OF BIOBANK
84. 6.84 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF BIOBANK
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF BIOBANK
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF BIOBANK
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE OF BIOBANK
101. 6.101 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TYPE OF BIOBANK, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TYPE OF BIOBANK, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.2.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.3.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.4.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.5.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.6.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.7.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.8.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.9.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.10.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.11.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.12.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.13.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.14.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.15.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.16.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.17.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.18.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.19.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.20.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.21.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.22.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.23.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.24.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.25.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.26.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.27.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.28.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.29.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY TYPE OF BIOBANK, 2025-2035 (USD Billion)
  3. 7.30.3 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Human Biobanking Ownership Market Segmentation

Human Biobanking Ownership Market By Application (USD Billion, 2025-2035)

Research
Clinical Trials
Personalized Medicine
Disease Prevention

Human Biobanking Ownership Market By Type of Biobank (USD Billion, 2025-2035)

Public Biobanks
Private Biobanks
Commercial Biobanks

Human Biobanking Ownership Market By Sample Type (USD Billion, 2025-2035)

Blood Samples
Tissue Samples
Cell Lines
Biological Fluids

Human Biobanking Ownership Market By End Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Academic Institutions
Human Biobanking Ownership Market Providers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”